Investment Adjustment Overview - Company announced an adjustment to increase investment in its subsidiary, Sportsoul Health Technology Co., Ltd. (Vietnam) from the originally planned $24.72 million to $20.52 million [2][10] - The new investment structure will result in the company directly holding 95% of the subsidiary's registered capital, while the subsidiary's total registered capital will increase to $21.6 million [4][5] Investment Details - The investment will be made through the company's own funds and self-raised funds, with the company contributing $20.52 million directly [2][4] - The previous plan involved contributions from both the company and Cyverce LLC according to their respective shareholding ratios [2][3] Board Meeting and Approval - The company's board of directors held a meeting on July 29, 2025, where the investment adjustment was unanimously approved [9][15] - The decision does not require shareholder approval as per relevant regulations [9] Purpose and Impact of Investment - The adjustment is aimed at aligning with local policies and market risks, enhancing operational capacity, and improving overall competitiveness and sustainable development [10] - The investment is not expected to significantly impact the company's existing business operations or financial status [10] Compliance and Documentation - The investment agreement will be effective upon completion of necessary internal approvals and government approvals [8] - The company will maintain compliance with legal requirements and ensure timely disclosure of investment progress [12]

青岛三柏硕健康科技股份有限公司（以下简称"公司"）第二届董事会第十次会议于2025年7月29日以现 场和通讯方式召开，会议通知于2025年7月25日以通讯方式送达。经全体董事一致同意豁免本次董事会 会议通知时限。会议应出席董事7名，实际出席董事7名。公司董事长朱希龙先生主持本次会议。会议的 召集、召开符合《中华人民共和国公司法》等法律法规及《青岛三柏硕健康科技股份有限公司章程》的 规定。公司监事、高级管理人员列席本次会议。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：001300 证券简称：三柏硕 公告编号：2025-036 青岛三柏硕健康科技股份有限公司 第二届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 与会董事对本次会议的全部议案进行了充分讨论，审慎表决，形成如下决议： 一、审议通过：《关于调整向控股孙公司增加投资的议案》 表决情况：7票同意，0票反对，0票弃权。 具体内容详见公司同日刊登在《证券时报》《证券日报》《中国证券报》《上海证券报》《经济参考 报》和巨潮资讯网（www.cninfo.com.cn）的《 ...

Group 1 - The core point of the article is that Sanbai Shuo announced the approval of an investment adjustment towards its controlling subsidiary during the 10th meeting of its second board of directors [2] Group 2 - The announcement was made on the evening of July 29, indicating a strategic move by the company to enhance its investment in a subsidiary [2] - The decision reflects the company's ongoing commitment to strengthen its operational capabilities and market position through increased investment [2]

证券代码：001300 证券简称：三柏硕 公告编号：2025-037 青岛三柏硕健康科技股份有限公司 关于调整向控股孙公司增加投资的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 基于中国境内及越南当地相关政策和市场风险变化，根据项目实施需要，拟 将投资方案由"海硕投资与塞沃斯以自有资金和自筹资金按照各自持股比例合计 向越南三柏硕增加投资2,472万美元"调整为"公司以自有资金和自筹资金直接 向越南三柏硕增加投资2,052万美元（具体投资和注册资本变更进程，根据越南 三柏硕实际生产经营需要进行变更）"。投资完成后公司直接持有越南三柏硕注 册资本2,052.00万美元，持股比例95%；海硕投资直接持有越南三柏硕注册资本 64.80万美元，持股比例3%；塞沃斯直接持有越南三柏硕43.20万美元，持股比例 2%。投资完成后，越南三柏硕成为公司控股子公司。 调整前投资情况： 青岛三柏硕健康科技股份有限公司 OCEAN MASTER INVESTMENTS,INC CYVERCE LLC SPORTSOUL HEALTH TECHNOLOGY CO.,LTD 增加 ...

证券代码：001300 证券简称：三柏硕 公告编号：2025-036 青岛三柏硕健康科技股份有限公司 具体内容详见公司同日刊登在《证券时报》《证券日报》《中国证券报》《上 海证券报》《经济参考报》和巨潮资讯网（www.cninfo.com.cn）的《关于调整向 控股孙公司增加投资的公告》（公告编号：2025-037）。 本议案已经公司董事会战略与投资委员会审议通过。 二、备查文件 1、青岛三柏硕健康科技股份有限公司第二届董事会第十次会议决议。 特此公告。 青岛三柏硕健康科技股份有限公司董事会 第二届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 青岛三柏硕健康科技股份有限公司（以下简称"公司"）第二届董事会第十 次会议于 2025 年 7 月 29 日以现场和通讯方式召开，会议通知于 2025 年 7 月 25 日以通讯方式送达。经全体董事一致同意豁免本次董事会会议通知时限。会议应 出席董事 7 名，实际出席董事 7 名。公司董事长朱希龙先生主持本次会议。会议 的召集、召开符合《中华人民共和国公司法》等法律法规及《青岛三柏硕健康科 技 ...

[Current Period Performance Forecast](index=1&type=section&id=I.%20Current%20Period%20Performance%20Forecast) The company anticipates a significant year-over-year decline in net profit attributable to shareholders and non-recurring net profit for the first half of 2025, with net profit expected to range from **RMB 7 million to RMB 10 million**, a **45.91% to 62.14% decrease**, and non-recurring net profit from **RMB 3 million to RMB 6 million**, a **51.22% to 75.61% decrease** Performance Forecast Summary | Item | Current Reporting Period (January 1 - June 30, 2025) | Prior Period | | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders of Listed Company** | Profit: RMB 7 million – RMB 10 million | Profit: RMB 18.4887 million | | Year-over-Year Change | Decrease: 62.14% - 45.91% | - | | **Net Profit After Deducting Non-Recurring Gains and Losses** | Profit: RMB 3 million – RMB 6 million | Profit: RMB 12.3007 million | | Year-over-Year Change | Decrease: 75.61% - 51.22% | - | | **Basic Earnings Per Share** | Profit: RMB 0.0288/share – RMB 0.0412/share | Profit: RMB 0.0758/share | [Communication with Accounting Firm](index=1&type=section&id=II.%20Communication%20with%20Accounting%20Firm) The company has pre-communicated the performance forecast with its accounting firm, finding no significant discrepancies, though this forecast remains unaudited - The company has pre-communicated the performance forecast with its accounting firm, with **no major discrepancies** identified, but this forecast remains **unaudited**[4](index=4&type=chunk) [Explanation of Performance Changes](index=1&type=section&id=III.%20Explanation%20of%20Performance%20Changes) The primary reasons for the performance decline are uncertainties in international trade policies and tariff adjustments, leading to reduced procurement demand from some clients and a decrease in the company's overseas orders - Performance changes are attributed to **international trade policy uncertainties** and **tariff adjustments**, resulting in reduced customer demand and a **decrease in overseas orders**[5](index=5&type=chunk) [Risk Warning](index=1&type=section&id=IV.%20Risk%20Warning) The company advises investors that this performance forecast is a preliminary estimate by the financial department, and the final data will be based on the officially disclosed 2025 semi-annual report, urging investors to be aware of investment risks - This performance forecast is a **preliminary estimate**, with final financial data subject to the **2025 semi-annual report**, and investors are advised to **exercise caution** regarding investment risks[6](index=6&type=chunk)[7](index=7&type=chunk)

三柏硕（001300）公告，预计2025年1月1日-2025年6月30日归属于上市公司股东的净利润为700万元– 1000万元，同比下降62.14%-45.91%；扣除非经常性损益后的净利润为300万元–600万元，同比下降 75.61%-51.22%。基本每股收益为0.0288元/股–0.0412元/股，同比下降62.14%-45.91%。公司业绩变动主 要受国际贸易政策不确定性及关税调整等不利因素影响，部分客户采购需求收缩，产品海外订单量减 少。 ...

Core Viewpoint - Qingdao Sanbaisuo Health Technology Co., Ltd. has approved the use of up to RMB 500 million of temporarily idle raised funds for cash management, ensuring that it does not affect the normal investment plans and safety of the raised funds [1][3]. Group 1: Cash Management Approval - The company held its 8th meeting of the 2nd Board of Directors and the 2nd Supervisory Board on April 25, 2025, where it approved the proposal for cash management using idle raised funds [1]. - The cash management period is set for 12 months from the date of approval, with individual investment products not exceeding 12 months [1]. Group 2: Investment Products Overview - The company has recently invested in various financial products using idle raised funds, including structured deposits and wealth management products from banks [1][2]. - Specific investments include: - RMB 4 million in a structured deposit with a 1.95% expected annual return [1]. - RMB 6 million in a 29-day structured deposit with an expected return of 1.85% [1]. - RMB 84 million in a structured deposit with a 2.47% expected return [1][2]. Group 3: Impact on Operations - The use of idle raised funds for cash management is aimed at optimizing the efficiency of fund usage without affecting the normal operations of the company's main business [3]. - The cash management strategy is expected to generate additional investment income, enhancing the overall performance of the company and providing better returns for shareholders [3]. Group 4: Compliance and Risk Management - The company emphasizes that the cash management activities comply with relevant regulations and internal control systems, ensuring that there is no change in the intended use of the raised funds [2][3]. - The company has established measures to monitor and control investment risks associated with cash management [3].

证券代码：001300 证券简称：三柏硕 公告编号：2025-034 青岛三柏硕健康科技股份有限公司 关于使用部分暂时闲置募集资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 二、关联关系说明 公司与华夏银行股份有限公司青岛城阳支行、交通银行股份有限公司青岛分行、 中信银行股份有限公司青岛城阳支行不存在关联关系。 三、投资风险及风险控制措施 青岛三柏硕健康科技股份有限公司（以下简称"公司"）于2025年4月25日分 别召开了第二届董事会第八次会议、第二届监事会第八次会议，审议通过了《关 于使用部分暂时闲置募集资金进行现金管理的议案》，同意在确保不影响募集资 金投资计划正常进行和募集资金安全的情况下，公司使用最高不超过人民币5亿 元的暂时闲置募集资金进行现金管理，使用期限自董事会审议通过之日起12个月 内，单个投资产品的投资期限不超过12个月。额度范围内资金可循环滚动使用。 具体内容详见公司于2025年4月28日披露的《关于使用部分暂时闲置募集资金进 行现金管理的公告》（公告编号：2025-025）。 根据上述决议，公司近期使用闲置募集 ...

Core Points - Sanbai Shuo announced that its wholly-owned subsidiary, Qingdao Yuyang Sports Technology Co., Ltd., applied for a comprehensive credit limit of up to 10 million RMB from the Qingdao branch of Bank of Communications, with Sanbai Shuo providing a maximum guarantee of 11 million RMB [1] - The company and its subsidiary have been approved to apply for a total credit limit of up to 800 million RMB for the year 2025, which includes the current application [1] - The internal approval procedures for the credit and guarantee have been completed, and the amounts are within the previously approved limits, thus no further board or shareholder approval is required [1] Company Financials - Qingdao Yuyang Sports Technology Co., Ltd. was established on January 10, 2018, with a registered capital of 13 million RMB, focusing on the production and sales of leisure sports and fitness equipment [2] - As of March 31, 2025, the company's total assets were 11.0185 million RMB, total liabilities were 9.9709 million RMB, and net assets were 1.0476 million RMB [2] - As of December 31, 2024, the audited financials showed total assets of 13.0494 million RMB, total liabilities of 12.2788 million RMB, and net assets of 0.7706 million RMB [2] Guarantee Details - The guarantee provided by Sanbai Shuo is a joint liability guarantee covering all principal debts, interest, compound interest, penalties, and costs related to the enforcement of claims [2] - As of the announcement date, the total external guarantees provided by the company and its subsidiary amounted to 41 million RMB, which represents 38.54% of the latest audited net assets [2]